1. Feng Y, Feng X, Lv Y. Worldwide burden of retinoblastoma from 1990 to 2021. Ophthalmic Res 2024; 67: 672-682.
2. Zhou M, Tang J, Fan J, Wen X, Shen J, Jia R, et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia Pac J Ophthalmol 2024; 13: 100058.
3. Chen J, Cao X, Xu S, Chen X, Xie R, Ye G, et al. Global, regional, and national burden of retinoblastoma in infants and young children: Findings from the global burden of disease study 1990–2021. eClinicalMedicine 2024; 76: 102860.
4. Pareek A, Kumar D, Pareek A, Gupta MM, Jeandet P, Ratan Y, et al. Retinoblastoma: An update on genetic origin, classification, conventional to next-generation treatment strategies. Heliyon 2024; 10: e32844.
5. O’Connor DP, Kay EW, Leader M, Murphy GM, Atkins GJ, Mabruk MJ. A high degree of chromosomal instability at 13q14 in cutaneous squamous cell carcinomas: indication for a role of a tumour suppressor gene other than Rb. Mol Pathol 2001; 54: 165-169.
6. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245-2262.
7. McEvoy J, Nagahawatte P, Finkelstein D, Richards-Yutz J, Valentine M, Ma J, et al. RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget 2014; 5: 438-450.
8. Shields CL, Lally SE, Leahey AM, Jabbour PM, Caywood EH, Schwendeman R, et al. Targeted retinoblastoma management: When to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr Opin Ophthalmol 2014; 25: 374-385.
9. Shahsavari M, Mashayekhi A. Pharmacotherapy for retinoblastoma. J Ophthalmic Vis Res 2009; 4: 169-173.
10. Munier FL, Beck-Popovic M, Chantada GL, Cobrinik D, Kivelä TT, Lohmann D, et al. Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”. Prog Retin Eye Res 2019; 73: 100764.
11. Paez-Escamilla M, Bagheri N, Teira LE, Corrales-Medina FF, Harbour JW. Intracameral topotecan hydrochloride for anterior chamber seeding of retinoblastoma. JAMA Ophthalmol 2017; 135: 1453-1454.
12. Shields CL, Shields JA, Kiratli H, De Potter PV. Treatment of retinoblastoma with indirect ophthalmoscope laser photocoagulation. J Pediatr Ophthalmol Strabismus 1995; 32: 317-322.
13. Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: A 2020 review. Indian J Ophthalmol 2020; 68: 2356-2365.
14. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013; 154: 442-451.
15. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013; 152: 1173-1183.
16. Naert T, Colpaert R, Van Nieuwenhuysen T, Dimitrakopoulou D, Leoen J, Haustraete J, et al. CRISPR/Cas9 mediated knockout of rb1 and rbl1 leads to rapid and penetrant retinoblastoma development in Xenopus tropicalis. Sci Rep 2016; 6: 35264.
17. Bassett AR, Tibbit C, Ponting CP, Liu J-L. Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system. Cell Rep 2013; 4: 220-228.
18. Raicu A-M, Castanheira P, Arnosti DN. Retinoblastoma protein activity revealed by CRISPRi study of divergent Rbf1 and Rbf2 paralogs. G3  2024; 14: jkae238.
19. Wells J, Yan PS, Cechvala M, Huang T, Farnham PJ. Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase. Oncogene 2003; 22: 1445-1460.
20. Kareta MS, Gorges LL, Hafeez S, Benayoun BA, Marro S, Zmoos AF, et al. Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell 2015; 16: 39-50.
21. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8: 671-682.
22. Dyson NJ. RB1: A prototype tumor suppressor and an enigma. Genes Dev 2016; 30: 1492-1502.
23. Sage J. The retinoblastoma tumor suppressor and stem cell biology. Genes Dev 2012; 26: 1409-1420.
24. Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 2013; 14: 297-306.
25. Marshall AE, Roes MV, Passos DT, DeWeerd MC, Chaikovsky AC, Sage J, et al. RB1 deletion in retinoblastoma protein pathway-disrupted cells results in DNA damage and cancer progression. Mol Cell Biol 2019; 39: e00105-19.
26. Knudsen ES, Knudsen KE. Tailoring to RB: Tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 8: 714-724.
27. Gelot C, Magdalou I, Lopez BS. Replication stress in Mammalian cells and its consequences for mitosis. Genes (Basel) 2015; 6: 267-298.
28. Jagadeesan M, Khetan V, Mallipatna A. Genetic perspective of retinoblastoma: From present to future. Indian J Ophthalmol 2016; 64: 332-336.
29. Shields JA, Shields CL. Intraocular tumors: An atlas and textbook: Lippincott Williams & Wilkins. 2008, p. 574.
30. Zimmerman LE, Burns RP, Wankum G, Tully R, Esterly JA. Trilateral retinoblastoma: Ectopic intracranial retinoblastoma associated with bilateral retinoblastoma. J Pediatr Ophthalmol Strabismus 1982; 19: 320-325.
31. Knudson AG, Jr. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68: 820-823.
32. Munier FL, Thonney F, Girardet A, Balmer A, Claustre M, Pellestor F, et al. Evidence of somatic and germinal mosaicism in pseudo-low-penetrant hereditary retinoblastoma, by constitutional and single-sperm mutation analysis. Am J Hum Genet 1998; 63: 1903-1908.
33. Zhou L, Tong Y, Ho BM, Li J, Chan HYE, Zhang T, et al. Etiology including epigenetic defects of retinoblastoma. Asia Pac J Ophthalmol 2024; 13: 100072.
34. Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, Piovesan B, et al. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet 2008; 17: 1363-1372.
35. Tosi GM, Trimarchi C, Macaluso M, La Sala D, Ciccodicola A, Lazzi S, et al. Genetic and epigenetic alterations of RB2/p130 tumor suppressor gene in human sporadic retinoblastoma: Implications for pathogenesis and therapeutic approach. Oncogene 2005; 24: 5827-536.
36. Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Thériault BL, et al. Characterisation of retinoblastomas without RB1 mutations: Genomic, gene expression, and clinical studies. Lancet Oncol 2013; 14: 327-334.
37. Wu N, Jia D, Bates B, Basom R, Eberhart CG, MacPherson D. A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence. J Clin Invest 2017; 127: 888-898.
38. Janostiak R, Torres-Sanchez A, Posas F, de Nadal E. Understanding retinoblastoma post-translational regulation for the design of targeted cancer therapies. Cancers (Basel) 2022; 14: 1265.
39. Godbout R, Dryja TP, Squire J, Gallie BL, Phillips RA. Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature 1983; 304: 451-453.
40. Wiggs J, Nordenskjöld M, Yandell D, Rapaport J, Grondin V, Janson M, et al. Prediction of the risk of hereditary retinoblastoma, using DNA polymorphisms within the retinoblastoma gene. N Engl J Med 1988; 318: 151-157.
41. Friend SH, Horowitz JM, Gerber MR, Wang XF, Bogenmann E, Li FP, et al. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci U S A 1987; 84: 9059-9063.
42. Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 2011; 10: 2497-2503.
43. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 2015; 14: 130-146.
44. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3: 1427-1438.
45. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11: 558-572.
46. Linn P, Kohno S, Sheng J, Kulathunga N, Yu H, Zhang Z, et al. Targeting RB1 Loss in Cancers. Cancers (Basel) 2021; 13: 3737.
47. Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: From discovery to therapy. Cancer Discov 2016; 6: 353-367.
48. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov 2016; 6: 740-753.
49. DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: Phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res 2015; 21: 995-1001.
50. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11: R77.
51. McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F, et al. Mechanisms of resistance to CDK4/6 inhibitors: Potential implications and biomarkers for clinical practice. Front Oncol 2019; 9: 666.
52. Knudsen ES, Witkiewicz AK. The strange case of CDK4/6 inhibitors: Mechanisms, resistance, and combination strategies. Trends Cancer 2017; 3: 39-55.
53. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997; 57: 1634-1637.
54. Brantley MA, Jr., Harbour JW. Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res 2000; 60: 4320-4323.
55. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992; 70: 993-1006.
56. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18: 753-761.
57. Alsina M, Landolfi S, Aura C, Caci K, Jimenez J, Prudkin L, et al. Cyclin E amplification/overexpression is associated with poor prognosis in gastric cancer. Ann Oncol 2015; 26: 438-439.
58. Raizis AM, Racher HM, Foucal A, Dimaras H, Gallie BL, George PM. DNA hypermethylation/boundary control loss identified in retinoblastomas associated with genetic and epigenetic inactivation of the RB1 gene promoter. Epigenetics 2021; 16: 940-954.
59. Zheng C, Schneider JW, Hsieh J. Role of RB1 in human embryonic stem cell-derived retinal organoids. Dev Biol 2020; 462: 197-207.
60. Kanber D, Woestefeld J, Döpper H, Bozet M, Brenzel A, Altmüller J, et al. RB1-negative retinal organoids display proliferation of cone photoreceptors and loss of retinal differentiation. Cancers (Basel) 2022; 14: 2166.
61. Nag A, Khetan V. Retinoblastoma - A comprehensive review, update and recent advances. Indian J Ophthalmol 2024; 72: 778-788.
62. Ortiz MV, Dunkel IJ. Retinoblastoma. J Child Neurol. 2016; 31: 227-236.
63. Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, et al. Retinoblastoma. Nat Rev Dis Primers 2015; 1: 15021.
64. Kandalam M, Mitra M, Subramanian K, Biswas J. Molecular pathology of retinoblastoma. Middle East Afr J Ophthalmol 2010; 17: 217-223.
65. Rao R, Honavar SG. Retinoblastoma. Indian J Pediatr 2017; 84: 937-944.
66. Windle JJ, Albert DM, O’Brien JM, Marcus DM, Disteche CM, Bernards R, et al. Retinoblastoma in transgenic mice. Nature 1990; 343: 665-669.
67. Park J, Cui G, Hong J, Jeong H, Han M, Choi MS, et al. Human retinal organoid modeling defines developmental window and therapeutic vulnerabilities in MYCN-amplified retinoblastoma. Int J Mol Sci 2025; 26: 8675.
68. Tong B, Zeng J, Wu Y, Xiong W. Enhanced SOX2 expression in retinoblastoma tissues and peripheral blood is associated with the clinicopathological characteristics of the disease. Oncol Lett 2015; 9: 1244-1248.
69. Orellana ME, Belfort RN, Antecka E, Burnier MN, Jr. Immunohistochemical analysis of retinoblastoma cell phenotype using neuronal and glial cell markers. Arq Bras Oftalmol 2016; 79: 395-399.
70. Garcia JR, Gombos DS, Prospero CM, Ganapathy A, Penland RL, Chévez-Barrios P. Expression of angiogenic factors in invasive retinoblastoma tumors is associated with increase in tumor cells expressing stem cell marker Sox2. Arch Pathol Lab Med 2015; 139: 1531-1538.
71. Flores M, Goodrich DW. Retinoblastoma protein paralogs and tumor suppression. Front Genet 2022; 13: 818719.
72. Hilgendorf KI, Leshchiner ES, Nedelcu S, Maynard MA, Calo E, Ianari A, et al. The retinoblastoma protein induces apoptosis directly at the mitochondria. Genes Dev 2013; 27: 1003-1015.
73. Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991; 67: 293-302.
74. Zhu L, van den Heuvel S, Helin K, Fattaey A, Ewen M, Livingston D, et al. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 1993; 7: 1111-1125.
75. Claudio PP, Howard CM, Baldi A, De Luca A, Fu Y, Condorelli G, et al. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 1994; 54: 5556-5560.
76. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res 2010; 70: 3877-3883.
77. Ghafouri-Fard S, Khoshbakht T, Hussen BM, Dong P, Gassler N, Taheri M, et al. A review on the role of cyclin dependent kinases in cancers. Cancer Cell Int 2022; 22: 325.
78. Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway. Cancer Cell 2018; 34: 893-905.
79. Sinclair WD, Cui X. The effects of HER2 on CDK4/6 activity in breast cancer. Clin Breast Cancer 2022; 22: e278-e85.
80. Han Y, Wang J, Wang Z, Xu B. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and network meta-analysis. Curr Probl Cancer 2020; 44: 100606.
81. Chen M, Zhao Z, Wu L, Huang J, Yu P, Qian J, et al. E2F1/CKS2/PTEN signaling axis regulates malignant phenotypes in pediatric retinoblastoma. Cell Death Dis 2022; 13: 784.
82. Hiebert SW, Chellappan SP, Horowitz JM, Nevins JR. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev 1992; 6: 177-185.
83. Almasan A, Yin Y, Kelly RE, Lee EY, Bradley A, Li W, et al. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci U S A 1995; 92: 5436-5440.
84. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
85. Xu XL, Singh HP, Wang L, Qi DL, Poulos BK, Abramson DH, et al. Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature 2014; 514: 385-388.
86. Hagen J, Muniz VP, Falls KC, Reed SM, Taghiyev AF, Quelle FW, et al. RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner. Cancer Res 2014; 74: 6661-670.
87. Wang H, Bauzon F, Ji P, Xu X, Sun D, Locker J, et al. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice. Nat Genet 2010; 42: 83-88.
88. Zhang L, Wang C. F-box protein Skp2: A novel transcriptional target of E2F. Oncogene 2006; 25: 2615-2627.
89. Yung Y, Walker JL, Roberts JM, Assoian RK. A Skp2 autoinduction loop and restriction point control. J Cell Biol 2007; 178: 741-747.
90. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: Tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-449.
91. Mojica FJM, Díez-Villaseñor C, García-Martínez J, Almendros C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology (Reading) 2009; 155: 733-740.
92. Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N, et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 2014; 156: 935-949.
93. Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A 2012; 109: E2579-2586.
94. Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 2014; 507: 62-67.
95. Bhattacharya S, Satpati P. Insights into the mechanism of CRISPR/Cas9-based genome editing from molecular dynamics simulations. ACS Omega 2023; 8: 1817-1837.
96. Palermo G, Ricci CG, Fernando A, Basak R, Jinek M, Rivalta I, et al. Protospacer adjacent motif-induced allostery activates CRISPR-Cas9. J Am Chem Soc 2017; 139: 16028-16031.
97. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science 2016; 351: 84-88.
98. Kang M, Zuo Z, Yin Z, Gu J. Molecular mechanism of D1135E-induced discriminated CRISPR-Cas9 PAM recognition. J Chem Inf Model 2022; 62: 3057-3066.
99. Hu JH, Miller SM, Geurts MH, Tang W, Chen L, Sun N, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature 2018; 556: 57-63.
100. Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 2015; 523: 481-485.
101. Zuo Z, Liu J. Structure and dynamics of Cas9 HNH domain catalytic state. Sci Rep 2017; 7: 17271.
102. Zuo Z, Liu J. Cas9-catalyzed DNA cleavage generates staggered ends: Evidence from molecular dynamics simulations. Sci Rep 2016; 6: 37584.
103. Kirankumar PN, Ampeti S, Srivastava M, Sheikh RB, Sali SR, BV SS. Targeted epigenome editing with CRISPR technologies: Transforming cancer treatment strategies. Medtigo J Pharmacol 2025; 2: 1-13.
104. Kennedy EM, Bassit LC, Mueller H, Kornepati AVR, Bogerd HP, Nie T, et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 2015; 476: 196-205.
105. Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, et al. Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab 2016; 24: 685-700.
106. Zhen S, Lu JJ, Wang LJ, Sun XM, Zhang JQ, Li X, et al. In vitro and in vivo synergistic therapeutic effect of cisplatin with human papillomavirus16 E6/E7 CRISPR/Cas9 on cervical cancer cell line. Transl Oncol 2016; 9: 498-504.
107. Seeger C, Sohn JA. Complete spectrum of CRISPR/Cas9-induced mutations on HBV cccDNA. Mol Ther 2016; 24: 1258-1266.
108. Huang J, Li J, Xu X, Li K. Adeno-associated virus vectors in retinal gene therapy: Challenges, innovations, and future directions. Biomolecules 2025; 15: 940.
109. Arsenijevic Y, Berger A, Udry F, Kostic C. Lentiviral vectors for ocular gene therapy. Pharmaceutics 2022; 14: 1605.
110. Salman A, Kantor A, McClements ME, Marfany G, Trigueros S, MacLaren RE. Non-viral delivery of CRISPR/Cas cargo to the retina using nanoparticles: Current possibilities, challenges, and limitations. Pharmaceutics 2022;14: 1842.
111. Bae T, Kim H, Kim JH, Kim YJ, Lee SH, Ham BJ, et al. Specificity assessment of CRISPR genome editing of oncogenic EGFR point mutation with single-base differences. Molecules 2019; 25: 52.
112. Kong X, Li T, Yang H. AAV-mediated gene therapies by miniature gene editing tools. Sci China Life Sci 2024; 67: 2540-2553.
113. Garcia-Doval C, Jinek M. Molecular architectures and mechanisms of Class 2 CRISPR-associated nucleases. Curr Opin Struct Biol 2017; 47: 157-166.
114. Choi EH, Suh S, Sears AE, Hołubowicz R, Kedhar SR, Browne AW, et al. Genome editing in the treatment of ocular diseases. Exp Mol Med 2023; 55: 1678-1690.
115. Ceccaldi R, Rondinelli B, D’Andrea AD. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol 2016; 26: 52-64.
116. Samach A, Mafessoni F, Gross O, Melamed-Bessudo C, Filler-Hayut S, Dahan-Meir T, et al. CRISPR/Cas9-induced DNA breaks trigger crossover, chromosomal loss, and chromothripsis-like rearrangements. Plant Cell 2023; 35: 3957-3972.
117. Aussel C, Cathomen T, Fuster-García C. The hidden risks of CRISPR/Cas: Structural variations and genome integrity. Nat Commun 2025; 16: 7208.
118. Park SY, Feng Z, Zhang X, Tang Y, Richart D, Vorhies KE, et al. A versatile reporter platform for evaluating HDR- and NHEJ-based genome editing in airway epithelial cell cultures using an rAAV vector. Viruses 2025; 17: 821.
119. Danner E, Bashir S, Yumlu S, Wurst W, Wefers B, Kühn R. Control of gene editing by manipulation of DNA repair mechanisms. Mamm Genome 2017; 28: 262-274.
120. Yang F, Wang Y, Wang Q, Pang J, Liu G, Yang Y, et al. Efficient repair of human genetic defect by CRISPR/Cas9-mediated interlocus gene conversion. Life Med 2023; 2: lnad042.
121. Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med 2018; 24: 927-930.
122. Zhang T, Li J, Wang T, Zhao F, Sui T. No apparent p53 activation in CRISPR-engineered gene-edited rabbits. J Cell Mol Med 2021; 25: 10313-10317.
123. Moore T, Chao-Shern C, DeDionisio L, Christie KA, Nesbit MA. Gene editing for corneal stromal regeneration. Methods Mol Biol 2020; 2145: 59-75.
124. Wilbie D, Walther J, Mastrobattista E. Delivery aspects of CRISPR/Cas for in vivo genome editing. Acc Chem Res 2019; 52: 1555-1564.
125. Yu W, Wu Z. Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases. Adv Drug Deliv Rev 2021; 168: 181-195.
126. Yang X, Zhou S, Zeng J, Zhang S, Li M, Yue F, et al. A biodegradable lipid nanoparticle delivers a Cas9 ribonucleoprotein for efficient and safe in situ genome editing in melanoma. Acta Biomater 2024; 190: 531-547.
127. Ramakrishnan M, Kaul R, Sharma A, Ahmad Z, Vijayakanth V, Keerthana K, et al. CRISPR RNP-mediated transgene-free genome editing in plants: advances, challenges and future directions for tree species. Plant Cell Environ 2026; 49: 7636-7656.
128. Lotfi M, Farshchian Yazdi Z, Hashemi MR, Abbaszadegan MR, Sharif S. Guarding the genome: Strategies for off-target detection and minimization in CRISPR/Cas9 system. Expert Rev Mol Diagn 2025; 25: 883-902.
129. Tao J, Bauer DE, Chiarle R. Assessing and advancing the safety of CRISPR-Cas tools: From DNA to RNA editing. Nat Commun 2023; 14: 212.
130. Bao XR, Pan Y, Lee CM, Davis TH, Bao G. Tools for experimental and computational analyses of off-target editing by programmable nucleases. Nat Protoc 2021; 16: 10-26.
131. Liang Y, Chen F, Wang K, Lai L. Base editors: Development and applications in biomedicine. Front Med 2023; 17: 359-387.
132. Hua K, Han P, Zhu JK. Improvement of base editors and prime editors advances precision genome engineering in plants. Plant Physiol 2022; 188: 1795-1810.
133. Hoff G, Bertrand C, Piotrowski E, Thibessard A, Leblond P. Genome plasticity is governed by double strand break DNA repair in streptomyces. Sci Rep 2018; 8: 5272.
134. Li Z, Ma R, Liu D, Wang M, Zhu T, Deng Y. A straightforward plant prime editing system enabled highly efficient precise editing of rice Waxy gene. Plant Sci 2022; 323: 111400.
135. Hossain H, Sayeed SSB, Islam S, Ahmad T, Brishty KA, Chowdhury MSR, et al. Prime editing, CRISPR-Cas9, and nanocas genome editing for cancer treatment. Mol Biotechnol 2026; 68: 2630-2658.
136. Hu X, Zhang B, Li X, Li M, Wang Y, Dan H, et al. The application and progression of CRISPR/Cas9 technology in ophthalmological diseases. Eye (Lond) 2023; 37: 607-617.
137. Wiley LA, Burnight ER, Songstad AE, Drack AV, Mullins RF, Stone EM, et al. Patient-specific induced pluripotent stem cells (iPSCs) for the study and treatment of retinal degenerative diseases. Prog Retin Eye Res 2015; 44: 15-35.
138. Bassuk AG, Zheng A, Li Y, Tsang SH, Mahajan VB. Precision medicine: Genetic repair of retinitis pigmentosa in patient-derived stem cells. Sci Rep 2016; 6: 19969.
139. Burnight ER, Gupta M, Wiley LA, Anfinson KR, Tran A, Triboulet R, et al. Using CRISPR-Cas9 to generate gene-corrected autologous iPSCs for the treatment of inherited retinal degeneration. Mol Ther 2017; 25: 1999-2013.
140. Sanjurjo-Soriano C, Erkilic N, Baux D, Mamaeva D, Hamel CP, Meunier I, et al. Genome editing in patient iPSCs corrects the most prevalent USH2A mutations and reveals intriguing mutant mRNA expression profiles. Mol Ther Methods Clin Dev 2020; 17: 156-73.
141. McEvoy J, Flores-Otero J, Zhang J, Nemeth K, Brennan R, Bradley C, et al. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 2011; 20: 260-275.
142. Dyer MA, Bremner R. The search for the retinoblastoma cell of origin. Nat Rev Cancer 2005; 5: 91-101.
143. Kuwahara A, Ozone C, Nakano T, Saito K, Eiraku M, Sasai Y. Generation of a ciliary margin-like stem cell niche from self-organizing human retinal tissue. Nat Commun 2015; 6: 6286.
144. Nakano T, Ando S, Takata N, Kawada M, Muguruma K, Sekiguchi K, et al. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell 2012; 10: 771-785.
145. Deng WL, Gao ML, Lei XL, Lv JN, Zhao H, He KW, et al. Gene correction reverses ciliopathy and photoreceptor loss in iPSC-derived retinal organoids from retinitis pigmentosa patients. Stem Cell Reports 2018; 10: 1267-1281.
146. Swaroop A, Kim D, Forrest D. Transcriptional regulation of photoreceptor development and homeostasis in the mammalian retina. Nat Rev Neurosci 2010; 11: 563-576.
147. Mellough CB, Bauer R, Collin J, Dorgau B, Zerti D, Dolan DWP, et al. An integrated transcriptional analysis of the developing human retina. Development 2019; 146: dev169474.
148. Liu H, Zhang Y, Zhang Y-Y, Li Y-P, Hua Z-Q, Zhang C-J, et al. Human embryonic stem cell-derived organoid retinoblastoma reveals a cancerous origin. Proc Natl Acad Sci U S A 2020; 117: 33628-33638.
149. Zheng SY, Su YY, Cai FL, Xu DF, Xu YQ. From mechanisms to precision medicine: The role of organoids in studying the gut microbiota-tumor microenvironment axis. Front Microbiol 2025; 16: 1669482.
150. Boehnke K, Iversen PW, Schumacher D, Lallena MJ, Haro R, Amat J, et al. Assay establishment and validation of a high-throughput screening platform for three-dimensional patient-derived colon cancer organoid cultures. J Biomol Screen 2016; 21: 931-941.
151. Conklin JF, Baker J, Sage J. The RB family is required for the self-renewal and survival of human embryonic stem cells. Nat Commun 2012; 3: 1244.
152. Kanazhevskaya LY, Zhdanova PV, Chernonosov AA, Koval VV. Off-target interactions in the CRISPR-Cas9 Machinery: Mechanisms and outcomes. Biochem Biophys Rep 2025; 43: 102134.
153. Ganguly A, Shields CL. Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis 2010; 16: 1292-1303.
154. Aldiri I, Xu B, Wang L, Chen X, Hiler D, Griffiths L, et al. The dynamic epigenetic landscape of the retina during development, reprogramming, and tumorigenesis. Neuron 2017; 94: 550-568.
155. Liu P. Pan-cancer DNA methylation analysis and tumor origin identification of carcinoma of unknown primary site based on multi-omics. Front Genet 2021; 12: 798748.
156. Aubry A, Pearson JD, Huang K, Livne-Bar I, Ahmad M, Jagadeesan M, et al. Functional genomics identifies new synergistic therapies for retinoblastoma. Oncogene 2020; 39: 5338-5357.
157. Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, Faria D, et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 2009; 27: 199-204.
158. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 2000; 407: 592-598.
159. Xu XL, Fang Y, Lee TC, Forrest D, Gregory-Evans C, Almeida D, et al. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell 2009; 137: 1018-10131.
160. Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yokota Y, Inserra A, et al. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 2002; 62: 301-306.
161. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008; 8: 193-204.
162. Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, et al. DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther 2016; 160: 65-83.
163. Agrawal T, Maddileti S, Mariappan I. Generation and characterization of three CRISPR/Cas9 edited RB1 null hiPSC lines for retinoblastoma disease modelling. Stem Cell Res 2024; 76: 103373.
164. Park J, Cui G, Hong J, Jeong H, Han M, Choi MS, et al. Human retinal organoid modeling defines developmental window and therapeutic vulnerabilities in MYCN-amplified retinoblastoma. Int J Mol Sci 2025; 26: 8675.
165. Praharaj PP, Bhutia SK, Nagrath S, Bitting RL, Deep G. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. Biochim Biophys Acta Rev Cancer 2018; 1869: 117-127.
166. Tanaka N, Osman AA, Takahashi Y, Lindemann A, Patel AA, Zhao M, et al. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity. Oral Oncol 2018; 87: 49-57.
167. Zhao R, Feng Q, Xia Y, Liao L, Xie S. Iteration of tumor organoids in drug development: Simplification and integration. Pharmaceuticals (Basel) 2025; 18: 1540.
168. Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 2014; 511: 616-620.
169. Joshi H, Tuli HS, Ranjan A, Chauhan A, Haque S, Ramniwas S, et al. The pharmacological implications of flavopiridol: An updated overview. Molecules 2023; 28: 7530.
170. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 2014; 159: 1126-1139.
171. Xiao D, Yue M, Su H, Ren P, Jiang J, Li F, et al. Polo-like kinase-1 regulates Myc stabilization and activates a feedforward circuit promoting tumor cell survival. Mol Cell 2016; 64: 493-506.
172. Xu XL, Fang Y, Lee TC, Forrest D, Gregory-Evans C, Almeida D, et al. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell 2009; 137: 1018-1031.
173. Tan SH, Tan TK, Yokomori R, Liao M, Huang XZ, Yeoh AEJ, et al. TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia. Leukemia 2023; 37: 1969-1981.
174. Li J, Liu J, Xia W, Yang H, Sha W, Chen H. Deciphering the tumor microenvironment of colorectal cancer and guiding clinical treatment with patient-derived organoid technology: Progress and challenges. Technol Cancer Res Treat 2024; 23: 1-19.
175. Huang M-F, Wang Y-X, Chou Y-T, Lee D-F. Therapeutic strategies for RB1-deficient cancers: Intersecting gene regulation and targeted therapy. Cancers 2024; 16: 1558.
176. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-698.
177. Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, et al. Cells lacking the RB1 tumor suppressor gene are hyperdependent on aurora B kinase for survival. Cancer Discov 2019; 9: 230-247.
178. Parkhitko AA, Singh A, Hsieh S, Hu Y, Binari R, Lord CJ, et al. Cross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells. PLoS Genet 2021; 17: e1009354.
179. Gupta P, Zhao H, Hoang B, Schwartz EL. Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition. Br J Cancer 2022; 127: 969-975.
180. Aubry A, Yu T, Bremner R. Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy. Cell Death Discov 2020; 6: 2.
181. Faruq O, Ngo J, Iyer D, Nesson J, Shrestha M, Chang H. Targeting of SKP2 to combat drug resistance in multiple myeloma. Sci Rep 2025; 15: 37838.
182. Xiong Y, Liu W, Huang Q, Wang J, Wang Y, Li H, et al. Tigecycline as a dual inhibitor of retinoblastoma and angiogenesis via inducing mitochondrial dysfunctions and oxidative damage. Sci Rep 2018; 8: 11747.
183. Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov 2020; 10: 1174-1193.
184. Condorelli R, Spring L, O’Shaughnessy J, Lacroix L, Bailleux C, Scott V, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol 2018; 29: 640-645.
185. Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, et al. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nat Commun 2024; 15: 2287.
186. Iacovacci J, Brough R, Moughari FA, Alexander J, Kemp H, Tutt ANJ, et al. Proteogenomic discovery of RB1 defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets. Sci Adv 2025; 11: eadq9495.
187. Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 2019; 568: 511-516.
188. Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet 2017; 49: 1779-1784.
189. Carbajosa S, Pansa MF, Paviolo NS, Castellaro AM, Andino DL, Nigra AD, et al. Polo-like kinase 1 inhibition as a therapeutic approach to selectively target BRCA1-deficient cancer cells by synthetic lethality induction. Clin Cancer Res 2019; 25: 4049-4062.
190. Jung Y, Seo E, Yang S, Bae S, Kim JH, Jang HK, et al. Establishment and rescue of fibroblast cell lines carrying a nonsense mutation of RB1 by CRISPR-based base editing. Sci Rep 2025; 15: 25074.
191. Nishida K, Arazoe T, Yachie N, Banno S, Kakimoto M, Tabata M, et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 2016; 353: aaf8729.
192. Tu J, Huo Z, Liu M, Wang D, Xu A, Zhou R, et al. Generation of human embryonic stem cell line with heterozygous RB1 deletion by CRIPSR/Cas9 nickase. Stem Cell Res 2018; 28: 29-32.
193. Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR/Cas9 therapeutics: Progress and prospects. Signal Transduct Target Ther 2023; 8: 36.
194. Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med 2020; 26: 732-740.
195. Su S, Zou Z, Chen F, Ding N, Du J, Shao J, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology 2017; 6: e1249558.
196. Beane JD, Lee G, Zheng Z, Mendel M, Abate-Daga D, Bharathan M, et al. Clinical scale zinc finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma. Mol Ther 2015; 23: 1380-1390.
197. Norrie JL, Nityanandam A, Lai K, Chen X, Wilson M, Stewart E, et al. Retinoblastoma from human stem cell-derived retinal organoids. Nat Commun 2021; 12: 4535.
198. VandenDriessche T, Janssens M, Chuah MK. CRISPR and gene editing technologies for bleeding disorders. Ther Adv Hematol 2025; 16: 20406207251387402.
199. Cetin B, Erendor F, Eksi YE, Sanlioglu AD, Sanlioglu S. Advancing CRISPR genome editing into gene therapy clinical trials: Progress and future prospects. Expert Rev Mol Med 2025; 27: e16.
200. Liu H, Zhang Y, Zhang YY, Li YP, Hua ZQ, Zhang CJ, et al. Human embryonic stem cell-derived organoid retinoblastoma reveals a cancerous origin. Proc Natl Acad Sci U S A. 2020; 117: 33628-33638.
201. Canals I, Comella-Bolla A, Cepeda-Prado E, Avaliani N, Crowe JA, Oburoglu L, et al. Astrocyte dysfunction and neuronal network hyperactivity in a CRISPR engineered pluripotent stem cell model of frontotemporal dementia. Brain Commun 2023; 5: fcad158.
202. Iacovacci J, Brough R, Moughari FA, Alexander J, Kemp H, Tutt ANJ, et al. Proteogenomic discovery of RB1-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets. Sci Adv 2025; 11: eadq9495.
203. Huang MF, Wang YX, Chou YT, Lee DF. Therapeutic strategies for RB1-deficient cancers: Intersecting gene regulation and targeted therapy. Cancers (Basel) 2024; 16: 1558.
204. Aaes TL, Kaczmarek A, Delvaeye T, De Craene B, De Koker S, Heyndrickx L, et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep 2016; 15: 274-287.
205. Jiang J, Jiang Z, Luo Q, Chen X, Zhuang J, Chen J, et al. Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening. Cell Death Dis 2025; 17: 128.
206. Lee C, Kim JK. Genome maintenance in retinoblastoma: Implications for therapeutic vulnerabilities. Oncol Lett 2022; 23: 192.
207. Ewen-Campen B, Yang-Zhou D, Fernandes VR, González DP, Liu LP, Tao R, et al. Optimized strategy for in vivo Cas9-activation in Drosophila. Proc Natl Acad Sci U S A 2017; 114: 9409-9414.
208. Azeez SS, Hamad RS, Hamad BK, Shekha MS, Bergsten P. Advances in CRISPR-Cas technology and its applications: Revolutionising precision medicine. Frontiers in genome editing. 2024; 6: 1509924.
209. Omachi K, Miner JH. Comparative analysis of dCas9-VP64 variants and multiplexed guide RNAs mediating CRISPR activation. PloS One 2022; 17: e0270008.
210. Li A, Cartwright S, Yu A, Ho S-M, Schrode N, Deans PM, et al. Using the dCas9-KRAB system to repress gene expression in hiPSC-derived NGN2 neurons. STAR Protoc 2021; 2: 100580.
211. Yeo NC, Chavez A, Lance-Byrne A, Chan Y, Menn D, Milanova D, et al. An enhanced CRISPR repressor for targeted mammalian gene regulation. Nat Methods 2018; 15: 611-616.
212. Choudhury SR, Cui Y, Lubecka K, Stefanska B, Irudayaraj J. CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. Oncotarget 2016; 7: 46545.
213. Radzisheuskaya A, Shlyueva D, Müller I, Helin K. Optimizing sgRNA position markedly improves the efficiency of CRISPR/dCas9-mediated transcriptional repression. Nucleic Acids Res 2016; 44: e141.
214. Zhang X, Zhao L, Hambly B, Bao S, Wang K. Diabetic retinopathy: Reversibility of epigenetic modifications and new therapeutic targets Cell Biosci 2017; 7: 42.
215. Bassuk AG, Zheng A, Li Y, Tsang SH, Mahajan VB. Precision medicine: Genetic repair of retinitis pigmentosa in patient-derived stem cells. Sci Rep 2016; 6: 19969.
216. Suh S, Choi EH, Leinonen H, Foik AT, Newby GA, Yeh W-H, et al. Restoration of visual function in adult mice with an inherited retinal disease via adenine base editing. Nat Biomed Eng 2021; 5: 169-178.
217. She K, Liu Y, Zhao Q, Jin X, Yang Y, Su J, et al. Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration. Signal Transduct Targeted Ther 2023; 8: 57.
218. Gilbert Luke A, Horlbeck Max A, Adamson B, Villalta Jacqueline E, Chen Y, Whitehead Evan H, et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 2014; 159: 647-661.
219. Matharu N, Rattanasopha S, Tamura S, Maliskova L, Wang Y, Bernard A, et al. CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. Science 2019; 363: eaau0629.
220. Afshar AR, Pekmezci M, Bloomer MM, Cadenas NJ, Stevers M, Banerjee A, et al. Next-generation sequencing of retinoblastoma identifies pathogenic alterations beyond RB1 inactivation that correlate with aggressive histopathologic features. Ophthalmology 2020; 127: 804-813.
221. Vincent A, Natarajan V, Khetan V, Krishnakumar S, Parameswaran S. Retinoblastoma patient-derived stem cells-an in vivo model to study the role of RB1 in adipogenesis. Histochem Cell Biol 2022; 158: 181-192.
222. Schultz LE, Haltom JA, Almeida MP, Wierson WA, Solin SL, Weiss TJ, et al. Epigenetic regulators Rbbp4 and Hdac1 are overexpressed in a zebrafish model of RB1 embryonal brain tumor, and are required for neural progenitor survival and proliferation. Dis Model Mech 2018; 11: dmm034124.
223. Watanabe S, Cui B, Kiga K, Aiba Y, Tan X-E, Sato’o Y, et al. Composition and diversity of CRISPR-Cas13a systems in the genus Leptotrichia. Front Microbiol 2019; 10: 2838.
224. Zhou Q, Chen Y, Wang R, Jia F, He F, Yuan F. Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment. Genes Dis 2023; 10: 2414-2424.
225. Makarova KS, Koonin EV. Annotation and classification of CRISPR-Cas systems. Methods Mol Biol 2015; 1311: 47-75.
226. Yin L, Zhao F, Sun H, Wang Z, Huang Y, Zhu W, et al. CRISPR-Cas13a inhibits HIV-1 infection. Mol Ther Nucleic Acids 2020; 21: 147-155.
227. Li Z, Li Z, Cheng X, Wang S, Wang X, Ma S, et al. Intrinsic targeting of host RNA by Cas13 constrains its utility. Nat Biomed Eng 2024; 8: 177-192.
228. Kimchi O, Larsen BB, Dunkley ORS, Te Velthuis AJW, Myhrvold C. RNA structure modulates Cas13 activity and enables mismatch detection. Nat Biotechnol 2025; 1: 1-41.
229. Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, et al. RNA targeting with CRISPR–Cas13. Nature 2017; 550: 280-284.
230. Nguyen H, Wilson H, Jayakumar S, Kulkarni V, Kulkarni S. Efficient inhibition of HIV using CRISPR/Cas13d nuclease system. Viruses 2021; 13: 1850.
231. Yoo KH, Hennighausen L, Shin HY. Dissecting tissue-specific super-enhancers by integrating genome-wide analyses and CRISPR/Cas9 genome editing. J Mammary Gland Biol Neoplasia 2019; 24: 47-59.
232. Agrawal T, Maddileti S, Mariappan I. Generation and characterization of three CRISPR/Cas9 edited RB1 null hiPSC lines for retinoblastoma disease modelling. Stem Cell Res 2024; 76: 103373.
233. Kanber D, Woestefeld J, Döpper H, Bozet M, Brenzel A, Altmüller J, et al. RB1-negative retinal organoids display proliferation of cone photoreceptors and loss of retinal differentiation. Cancers 2022; 14: 2166.
234. Li Y-P, Wang Y-T, Wang W, Zhang X, Shen R-J, Jin K, et al. Second hit impels oncogenesis of retinoblastoma in patient-induced pluripotent stem cell-derived retinal organoids: Direct evidence for Knudson’s theory. PNAS Nexus 2022; 1: pgac162.
235. Knudsen ES, Hutcheson J, Vail P, Witkiewicz AK. Biological specificity of CDK4/6 inhibitors: Dose response relationship, in vivo signaling, and composite response signature. Oncotarget 2017; 8: 43678.
236. Suh S, Choi EH, Leinonen H, Foik AT, Newby GA, Yeh WH, et al. Restoration of visual function in adult mice with an inherited retinal disease via adenine base editing. Nat Biomed Eng 2021; 5: 169-178.
237. Pierce Eric A, Aleman Tomas S, Jayasundera Kanishka T, Ashimatey Bright S, Kim K, Rashid A, et al. Gene editing for CEP290-associated retinal degeneration. N Engl J Med 2024; 390: 1972-1984.
238. Pulman J, Botto C, Malki H, Ren D, Oudin P, De Cian A, et al. Direct delivery of Cas9 or base editor protein and guide RNA complex enables genome editing in the retina. Mol Ther Nucleic Acids 2024; 35: 102349.
239. Pulman J, Sahel JA, Dalkara D. New editing tools for gene therapy in inherited retinal dystrophies. CRISPR J 2022; 5: 377-388.
240. Mout R, Ray M, Lee YW, Scaletti F, Rotello VM. In vivo delivery of CRISPR/Cas9 for therapeutic gene editing: Progress and challenges. Bioconjug Chem 2017; 28: 880-884.
241. Rathore S, Verma A, Ratna R, Marwa N, Ghiya Y, Honavar SG, et al. Retinoblastoma: A review of the molecular basis of tumor development and its clinical correlation in shaping future targeted treatment strategies. Indian J Ophthalmol 2023; 71: 2662-2676.
242. Elchuri SV, Rajasekaran S, Miles WO. RNA-sequencing of primary retinoblastoma tumors provides new insights and challenges into tumor development. Front Genet 2018; 9: 170.
243. Hachem S, Yehya A, El Masri J, Mavingire N, Johnson JR, Dwead AM, et al. Contemporary update on clinical and experimental prostate cancer biomarkers: A multi-omics-focused approach to detection and risk stratification. Biology (Basel) 2024; 13: 762.
244. Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer 2024; 23: 9.
245. Cromer MK, Barsan VV, Jaeger E, Wang M, Hampton JP, Chen F, et al. Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells. Nat Commun 2022; 13: 4724.
246. Temming P, Arendt M, Viehmann A, Eisele L, Le Guin CH, Schündeln MM, et al. How eye-preserving therapy affects long-term overall survival in heritable retinoblastoma survivors. J Clin Oncol 2016; 34: 3183-3138.
247. Barro V, Nuñez JH, Gargallo-Margarit A, Sallent A, Aguilar M, Hernandez A. Bilateral insufficiency hip fractures after bariatric surgery. Osteoporos Int 2017; 28: 1495-1498.
248. Burgess DJ. Characterizing CRISPR off-target effects. Nat Rev Genet 2014; 15: 5.
249. Fix SM, Jazaeri AA, Hwu P. Applications of CRISPR genome editing to advance the next generation of adoptive cell therapies for cancer. Cancer Discov 2021; 11: 560-574.
250. Eyquem J, Mansilla-Soto J, Odak A, Sadelain M. 274. One-step generation of universal CAR T cells. Mol Ther 2016; 24: S109.
251. Vakulskas CA, Dever DP, Rettig GR, Turk R, Jacobi AM, Collingwood MA, et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med 2018; 24: 1216-1224.
252. Story BD, Thomasy SM, Adelman SA, Taghian T, Lopez Y, Ardon M, et al. Cerebrospinal delivery of a bidirectional AAV9 vector improves optic nerve and retinal pathology in a sheep model of Tay-Sachs disease. Mol Ther 2026; 34: 5498-5509.
253. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015; 520: 186-191.
254. Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, et al. p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. Nat Med 2018; 24: 939-946.
255. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 2019; 576: 149-157.
256. Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med 2019; 25: 249-254.
257. Gillmore Julian D, Gane E, Taubel J, Kao J, Fontana M, Maitland Michael L, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 2021; 385: 493-502.
258. Frangoul H, Altshuler D, Cappellini MD, Chen Y-S, Domm J, Eustace Brenda K, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med 2021; 384: 252-260.
259. Xu W, Zhang S, Qin H, Yao K. From bench to bedside: Cutting-edge applications of base editing and prime editing in precision medicine. J Transl Med 2024; 22: 1133.
260. Villiger L, Grisch-Chan HM, Lindsay H, Ringnalda F, Pogliano CB, Allegri G, et al. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat Med 2018; 24: 1519-1525.
261. Happi Mbakam C, Rousseau J, Lu Y, Bigot A, Mamchaoui K, Mouly V, et al. Prime editing optimized RTT permits the correction of the c.8713C>T mutation in DMD gene. Mol Ther Nucleic Acids 2022; 30: 272-285.
262. Villiger L, Joung J, Koblan L, Weissman J, Abudayyeh OO, Gootenberg JS. CRISPR technologies for genome, epigenome and transcriptome editing. Nat Rev Mol Cell Biol 2024; 25: 464-487.
263. Arbab M, Matuszek Z, Kray KM, Du A, Newby GA, Blatnik AJ, et al. Base editing rescue of spinal muscular atrophy in cells and in mice. Science 2023; 380: eadg6518.
264. Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018; 378: 625-635.
265. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017; 376: 836-847.
266. Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016; 375: 740-753.
267. Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities. Blood 2023; 141: 467-480.
268. Wellhausen N, O’Connell RP, Lesch S, Engel NW, Rennels AK, Gonzales D, et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci Transl Med 2023; 15: eadi1145.
269. Liu B, Liu Y, Zhang H, Huang J, Liu G. Progress of iPSC-derived retinal organoids in the study of inherited retinal diseases. Orphanet J Rare Dis 2025; 20: 552.
270. Rozanska A, Cerna-Chavez R, Queen R, Collin J, Zerti D, Dorgau B, et al. pRB-depleted pluripotent stem cell retinal organoids recapitulate cell state transitions of retinoblastoma development and suggest an important role for pRB in retinal cell differentiation. Stem Cells Transl Med 2022; 11: 415-433.
271. Liu H, Zhang Y, Zhang Y-Y, Li Y-P, Hua Z-Q, Zhang C-J, et al. Human embryonic stem cell-derived organoid retinoblastoma reveals a cancerous origin. Proc Natl Acad Sci U S A 2020; 117: 33628-33638.
272. Norrie JL, Nityanandam A, Lai K, Chen X, Wilson M, Stewart E, et al. Retinoblastoma from human stem cell-derived retinal organoids. Nat Commun 2021; 12: 4535.
273. Aubry A, Yu T, Bremner R. Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy. Cell Death Discov 2020; 6: 2.
274. Muller A, Sullivan J, Schwarzer W, Wang M, Park-Windhol C, Hasler PW, et al. High-efficiency base editing in the retina in primates and human tissues. Nat Med 2025; 31: 490-501.
275. Hochberg GKA, Shepherd DA, Marklund EG, Santhanagoplan I, Degiacomi MT, Laganowsky A, et al. Structural principles that enable oligomeric small heat-shock protein paralogs to evolve distinct functions. Science 2018; 359: 930-935.
276. Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, et al. RNA targeting with CRISPR–Cas13. Nature 2017; 550: 280-284.
277. Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, et al. RNA editing with CRISPR-Cas13. Science 2017; 358: 1019-1027.
278. Du Toit A. Restoring brown fat commitment. Nat Rev Mol Cell Biol 2016; 17: 204.